Lactobacillus fermentum CECT5716, LC40 is a probiotic strain isolated from human breast milk of healthy mothers and under patent of Biosearch Life.
Lactobacillus fermentum CECT5716 LC40 can modulate human defences, reducing the risk of infections and alleviating inflammatory responses in several chronic inflammatory diseases.
If you are interested to receive more information about this product, please give us your data in the following form and we will send you a PDF to your email.
• LC40 produces compounds that help to maintain the integrity of human gut.
• LC40 protects against intestinal infections.
Frequency of mothers suffering breast pain is higher during the first month of breastfeeding. Antibiotic consumption during pregnancy
or delivery is an important risk factor for mastitis development.
Lactobacillus fermentum CECT5716 might be used as an efficient strategy to prevent development of lactational mastitis in women through reduction of the Staphylococcus load in breast milk.
Less episodes of mastitis lead to a lesser use of antibiotics during breastfeeding and therefore a smaller risk of microbiota imbalance.
L. fermentum CECT5716 (LC40) could be an efficient treatment for breast pain during lactation associated with high level of Staphylococcus in breastmilk.
Arroyo R, Martín V, Maldonado A et al. Treatment of infectious mastitis during lactation: antibiotics versus oral administration of Lactobacilli isolated from breast milk. Clin Infect Dis 2010 15;50(12):1551-8. Jose A. Maldonado-
Lobón, Miguel A. Díaz-López et al. Lactobacillus fermentum CECT5716 reduces Staphylococcus load in the breast milk of lactating mothers suffering breast pain: A randomized controlled trial.
Breastfeed Med. 2015 Nov;10:425-32. JA. Hurtado et al. Lactobacillus fermentum CECT5716, a human milk probiotic strain, reduces the incidence and symptoms of mastitis in lactating women. Poster presented at Probiota 2016. Amsterdam.
BENEFITS FOR CHILD
Human Milk Probiotic Lactobacillus fermentum CECT5716 reduces the Incidence of Gastrointestinal and Upper Respiratory Tract Infections in Infants.
Maldonado et al. 2012, Hepatology and Nutrition.
The consumption of L. fermentum was related to a significant reduction of 71% in the incidence of gastrointestinal infections compared to the infants fed without the probiotic strain.
Gil-Campos et al. 2012, Pharmacological Research.
The singular origin of Hereditum® makes its range of strains an exceptional candidate for use in infant nutrition, functional foods, health supplements etc.
Their excellent probiotic potential and technological versatility ensures their maximum functionality and performance (e.g. dairy products, fermented or not, sugar rich matrices, infant formulas, supplements, and many others).
GMP –Good Manufacturing Practices- Food**
Accreditation ISO 17025
NDI (FDA): LC40 (Lactobacillus fermentum CECT5716)
GRAS (FDA): LC40 (Lactobacillus fermentum CECT5716)
QPS: All our strains are QPS in Europe.
in the World Intellectual
**xDesign, production and distribution of oils and probiotic area